Given the differences in occurrence of benign precursor stages – MMR-DCF for path_MLH1, dMMR adenomas for path_MSH2 and pMMR adenomas for path_PMS2 carriers (43, 44) – optimisation of colonoscopy procedures would need to be MMR gene–specific. The gene discussed is MSH2; the disease is adenoma.